Tofacitinib (Xeljanz▼): new measures to minimise risk of venous thromboembolism and of serious and fatal infections

This alert advises caution when used in patients with known risk factors for VTE in addition to the underlying disease. Patients > 65 years of age are at an increased risk of serious infections and should be treated with tofacitinib only in case of no alternative treatment.

Medicines and Healthcare products Regulatory Agency